歌禮(01672.HK)續漲31%創逾七個月高 旗下藥品被使用作新型肺炎臨床試驗
歌禮製藥(01672.HK)旗下藥品被使用作新型肺炎臨床試驗,該股承上周五急漲25%強勢,今早突破牛熊線(5.04元),最多再飆近57%高見6.5元,創逾七個月高,現造5.44元,續升31%,成交已達7,697萬股,涉資4.2億元。
歌禮公布,已收到相關醫療機構和研究人員申請使用公司研發ASC09複方片和利托那韋(Ritonavir)開展新型冠狀病毒(2019-nCoV)感染患者臨床試驗;且河南省衛健委於1月31日宣布已有3例確診新型冠狀病毒感染患者在服用洛匹那韋╱利托那韋等藥品後治癒。公司補充,利托那韋及ASC09複方片均為公司尚未獲得上市批文的產品。公司已於2020年1月25日向國家藥品監督管理局及其藥品審評中心申請將利托那韋及ASC09複方片納入國家應急通道。相關藥監部門已確認收到公司該等申請。歌禮製藥指,無法擔保公司能取得利托那韋及ASC09複方片上市批准或最終成功地營銷利托那韋及ASC09複方片。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.